MedTrace Logo

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

NCT04176848 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-02-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.

Conditions

Interventions

DRUG

CFI-400945

CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily

DRUG

Durvalumab

Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University Health Network, Toronto

    collaborator OTHER

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • David Cescon · University Health Network, PMH, Toronto ON

  • Andrew Robinson · Cancer Centre of Southeastern Ontario at Kingston, ON

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-10
Primary Completion
2022-09-15
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04176848 on ClinicalTrials.gov